BioSpace News Archive

Drug Development

bluebird bio Announces the Lifting of FDA Clinical Hold for Sickle Cell Disease and β-Thalassemia Studies

bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD, and the Phase 3 Northstar-2 (HGB-207) and Northstar-3 (HGB-212) studies of betibeglogene autotemcel gene therapy

June 7, 2021
·
9 min read
Business

Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel

Moderna and Medison Pharma Partner to Commercialize Moderna’s COVID-19 Vaccine Across Central Eastern Europe and Israel

June 7, 2021
·
5 min read
Elekta’s new strategy to focus on growth and access to radiation therapy

At Elekta’s (EKTA-B.ST) Capital Markets Day, CEO, Gustaf Salford , and members from his executive management team introduced the company’s mid-term strategy, called Access 2025. The strategy reflects the wor

June 7, 2021
·
3 min read
Bio NC

Results from Novan’s Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced positive proof-of-concept in vitro results and informative in vivo results with its new chemical entity (NCE), NVN4100, explored as a potential product candidate for topical antimicrobial indications in companion animal health.

June 7, 2021
·
8 min read
Biotech Bay

UCSF QBI and University College, London Identify Mutations in “U.K.” Strain of Coronavirus SARS-CoV-2 Responsible for Enhanced Transmissibility and Infectivity

Findings show key mutations and evolution of U.K. SARS-CoV-2 compared to earlier lineages account for upregulation of innate immune antagonists, which hamper immune response and allow for increased viral replication and duration of infection

June 7, 2021
·
7 min read
Drug Development

Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study

Neurana Pharmaceuticals, a biotechnology company focused on the treatment of neuromuscular conditions, today announced that 500 of its target 1,000 subjects have been enrolled in the Phase 3, RESUME-1 clinical study of tolperisone

June 7, 2021
·
2 min read
Biotech Bay

Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference

Nektar Therapeutics’ (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42 nd Annual Global Healthcare Conference on Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time .

June 7, 2021
·
1 min read
BioMidwest

Neovasc Reducer System Receives First National Reimbursement in Europe

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer® (“Reducer”) system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff Excluded Devices (HCTED) national catalogue.

June 7, 2021
·
9 min read
Business

Javara Appoints First CCO During Period of Accelerated Growth

Javara, a leading Integrated Research Organization focused on improving clinical trial access and outcomes, announced today that it has appointed Brenda Reese, BSN, RN, as its first chief commercial officer (CCO).

June 7, 2021
·
3 min read
Therapeutic Solutions International Reports Amplification of Cancer Specific Immune Responses Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC

Company Demonstrates Existing Platform Can Synergize with Multiple Antigen Specific Tumor Immunotherapies

June 7, 2021
·
2 min read